º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM
¶}³oÓª©¤D¦³·P©ó
Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×z
Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O
¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P
©Ò¥H , ³oÓª©
¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï
§Æ±æ¼ö¾x¬Oì«h
¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý
¬ß±æ
¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú̪º¦@¦Pµ§°O
¡yÅý§Ṳ́@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O
´Á«Ý±zªº°Ñ»P
ÁÂÁ¤j®a!
¤pªÑªF®ü¥~¤W¥«·|¦³ºÃ¼{¤]¤£¬O¨S¦³¹D²z
Ó¤H¥»¨³o¨â¦~¦Û¨§ë¸ê´N¦³¨â°_Ãþ¦ü®×¨Ò
1.»··~3307 2.¦í¸sÀç³y¨ÖÁÊ
¨¬°¤pªÑªF±¹ï¤jªÑªFªº³g°ý¥u¦³µL©`¦Ó¤w
©Ò¥HÁÙ¬O§Æ±æ½²¸³¤£½×¦³¥ô¦ó·QªkÁÙ¬O¯àÝÅU¤pªÑªFÅv¯q
u®ü¥~¤W¥«¡Aµ²ºâ°Ê§@¤@©w·|¦³¡A¥u¬Oµ²ºâªº¤è¦¡©Î±ø¥ó¦³«Ü¦hºØ¡A
®³µ²ºâªº®×¨Ò¨Ó¼L§ÚÁ¿ªºµ²ºâ¡AÁÙ¯u¤£ª¾¹DÅÞ¿è¬O¬Æ»ò¡A
Á٬ƻòÁÁ¨¥©Î¹DÅ¥¶î»¡¡A¬~½L.....·|¤£·Q¤Ó¦h? XD
Å¥¨ìµ²ºâ¨âÓ¦r¤§«áÂà´«ªº¸£³U½ĶY¬O ªÑ¼Æ´«²{ª÷¡AºMÂd¡A¨ì¥~°ê¤W¥«¡A¨º§Ú¤]·|¤£²n¡C
¤W±ªºµ²ºâ¬O³ÌÄꪺ¤è¦¡¡A§Ú¤]¦³ªÑ²¼¡A¤]¤£·|·Qn³oºØª¬ªp¡C
¦A»¡¤@¦¸¡Aµ²ºâ¦³«Ü¦hºØ¤è¦¡©M®×¨Ò¡A§O¥Î²³æªºª½Æ[¥h½Ķ¡A·PÁ¡C
©Î³\¤§«e¤å³¹¨S§âµ²ºâÁ¿±o§ó¥J²Ó¡AÅý¬Y¨Ç¤H²³æªº»~·|¡A³y¦¨§xÂZ¡A²`·P©êºp¡C
¦Ü©ó²{¹ê¤W§AÌ´N¤£¬O¤jªÑªF¡Aµ²ºâ¤è¦¡¡A³Ì«á´N¬O 51% ¥H¤WªºªÑ¼Æ¨M©w¡A
§AÌn§â®ü¥~¤W¥«·Q±o«Ü´Î¤]µL§«¡A«Ü¦h¨Æ±¡¦¹¤@®É©¼¤@®É¡A¤£µM·íªì¤ß®®¦b¥xÆW¶Ò¸ê¿³Âd°µÔ£?
³Ì«á¡A²q·Q¤j¡A±Í¤HµL·N»s³y¦¹ª©ªº§xÂZ¡A¦ý¹ï©ó³Q¼v®gªº©_©Ç»¡µü¡A¤£»¡©ú¤]«ÜÃø¹L¡A©êºp¤F¡C
¤]ÁÂÁ§A¤@ª½¥H¨Óªº¸ê°T´£¨Ñ¡A·PÁ¡C
¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-07-02
med.sina.com/article_detail_103_2_48264.html
·í«e¡AÀHµÛ¹ïªü¤ùÃþ¤îµhÃĦ¨Å}©Ê¾á¼~ªº¤é¯q¼W¥[¡A¶V¨Ó¶V¦hªº¤½¥q¥¿¦bP¤O©ó¶}µo¦³®Ä¦ý¤£¨ã¦³¦¨Å}©ÊªºªvÀøÃĪ«¡C«Dªü¤ùÃþÃĪ«ªºÃöª`«×©M»Ý¨D¤j´T¼W¥[¡C
¤µ¦~¦¨Ç®ÉÔ¡ABCC Researchµo¥¬³ø§i«ü¥X¡AÀHµÛ¯kµhªvÀøªº¤é¯q¦h¾Ç¬ì¤Æ¡B´À¥N©Ê«Dªü¤ùÃþÃĪ«¨Ï¥ÎªºÂX±i¤ÎÂå¥Î¤j³ÂÃĪ«ªº¤é¯q³Q±µ¨ü¡A¥¼¨Ó5¦~¥þ²y«Dªü¤ùÃþÃĪ«ªvÀø¥«³õ¹wp±N½¤@¿¡A¦b2022¦~¹F¨ì220»õ¬ü¤¸¡A¦b¹w´ú´Á¡]2018-2022¡^¤ºªº½Æ¦X¦~¼Wªø²v¡]CAGR¡^±N°ª¹F18.0%¡C
BCC Research«ü¥X¡A¦³5¤jÃþ«Dªü¤ùÃþÃĪ«¤è®×¥i¯à·|¨ú¥Nªü¤ùÃþÃĪ«¡A¥]¬A¡GÂå¥Î¤j³ÂÃĪ«¡Al¥Í©ó»¶´Ô¯ÀªºÃĪ«¡A§tÁ¡²ü¾JªºÃĪ«¡A§t£s-3¯×ªÕ»ÄªºÃĪ«¡A¦×¬r±ìµß¬r¯À¡C¨ä¤¤¡AÂå¥Î¤j³Â¬O¥þ²y³Ì¤jªº²Ó¤À¥«³õ¡A¦û¥þ²y¥«³õ¥÷ÃBªº73%¡A¸Ó²Ó¤À¥«³õ¦b2017¦~³W¼Ò¬°73»õ¬ü¤¸¡A¹w´ú´Á¤ºªºCAGR±N¹F¨ìÅå¤Hªº22.2%¡A2022¦~³W¼Ò¹F¨ì198»õ¬ü¤¸¤§¥¨¡A¦Ó±À°Ê¸Ó²Ó¤À¥«³õµo®iªºÃöÁä¦]¯À´N¬OÂå¥Î¤j³Â±±¨î¯kµhªº¤é¯q±Ä¥Î¡C
®Ú¾Ú¬ü°ê½Ã¥Í©M¤HÃþªA°È³¡¡]HHS¡^ªº¼Æ¾ÚÅã¥Ü¡A¦b¬ü°ê¡A¨C¤Ñ¦³116¤H¦º©óªü¤ùÃþÃĪ«¹L¶q¡C¦b2016¡A¬ü°ê¬ù¦³64000¨ÒÃĪ«¬ÛÃö¦º¤`¡A¨ä¤¤ªü¤ùÃþÃĪ«¬ÛÃö¦º¤`º¦´T³Ì°ª¡C¬ü°ê¯e¯f±±¨î©M¹w¨¾¤¤¤ß¡]CDC¡^µo¥¬ªº¤@¥÷³Ì·s³ø§iÅã¥Ü¡A±q2016¦~7¤ë¦Ü2017¦~9¤ë¡Aªü¤ùÃþÃĪ«¬ÛÃö«æ¶E´N¶E²v¦b¦U¤j¦{¿E¼W30%¡C¥h¦~¡A¨Ó¦ÛEndo»sÃĤ½¥qªº§ïª©ªü¤ùÃþ¤îµhÃÄOpana ER¦]³Q½T»{¥¼¯à¨¾¤îÀݥΡA³Q¬ü°êFDAn¨DºM¥«¡C
¤@«h´N·Q§â§A̤⤤¦³ªºÄw½Xµ¹»´©ö¬~¥X¨Ó~
rabbit¤j ´£¥XijÃD Åý»~·|±o¥HÂç²M
§óÁÂÁÂ
¤p³ì¤j
º©¹CªÌ¤j Âç²M³oÓ¼~¼{ ¸Ñ¶}¤j®aªº¤ßµ²
¤p§Ì¤]§ä¨ì³ß±d¡XKYªº·s»D ´£½Ð°Ñ¦Ò
¡u ³ß±d-KY¹O90%ªÑªFÄ@Äò«ùªÑu°ê¥~±¾µP ¬ü´ä¬°º¿ï ¡v
news.cnyes.com/news/id/4033761
¥Íª«¬Û¦üÃļt³ß±d - KY(6540-TW) ªí¥Ü¡A®Ú¾Ú¤½¥q»PªÑªF³sô«á²Îp¡A¦³¶W¹L 90% ªºªÑªFÄ@·NÄ~Äò«ù¦³ªÑ²¼¡A¦A¨ì°ê¥~±¾µP¡A¥Ø«eªì¨Bªº®ü¥~±¾µPpµe¡A±N¬O¥H¬ü°ê¸ò»´ä¬°¥Dn±¾µP¥«³õ¿ï¶µ¡C
¥t¥~
³¯ÀR¤j «Øijµ²ºâÃöª©
¤p§Ì¥H¬°°Q½×¥i¥HÂç²M»~·| Åý¨Æ¹ê§e²{ À³¦³¨ä¥¿±¥\¯à
¤ß®®ªÑªF«ùªÑ¬JµM¤£·|³Qµ²ºâ ¥»ª©¤]´NÅý¥¦«ùÄò©M¤ß®®£¸°_¦¨ªø
°ß½Ð¤j®a´£¥XijÃD®É ½Ð¥ý¤©¥H¹LÂo
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a¡I
¥»¨Ó¤£·Q¦A©µÄò³oÓ¸ÜÃD¡A¦ý¬O¿ù»~ªº¸ê°T¤£¼á²M·|³y¦¨«Ü¦h»~¾É
³Â·Ð¤j®a«áÄò¤£n¦A¹ï³oÓ¸ÜÃD¶i¦æ¦^À³°Q½×¡A·P®¦
¡uµ´¹ï¨S¦³¨ì°ê¥~¤W¥««á¡A¤â¤WªÑ²¼·|³Qµ²ºâ³oºØ¨Æ±¡¡v
¤f»¡µL¾Ì¡Aª½±µÁ|¨Ò
1. ©_´º¥ú¹quNASDAQ¤W¥«
. 2005/8¡G²×¤î¿³Âd¶R½æ¡AµLµ²ºâ¡A¿³Âd³Ì«á¤@¤Ñ»ù®æ90¥ª¥k
. 2006/3/31¡G¦bNASDAQ IPO¡AªÑªF¥i¥H¥Î·í¤éIPO»ù®æ9¬ü¤¸½æµ¹¨÷°Ó¡A©Î¬Oª½±µ¦b¥«³õ¶R½æ
2. «Ø¥ÃºMÂd¡A´M¨D®ü¥~IPO¡AµLµ²ºâ
3. ³ß±dºMÂd¡AµLµ²ºâ¡A¦ý¬O¦]¬°¬OKY¤½¥qªº½t¬G¡A¤½¥q¥²¶·¦³¶R¦^¾÷¨î¡A¦ý¬OªÑªF¥i¥H¨M©w¬O§_Åý¤½¥q¶R¦^©Î¬OÄ~Äò¸òÀH¤½¥q
¥xÆW¥«³õµLªk¦X²z¤ÏÀ³¥«È,¥h°ê¥~¹ïªÑªF·íµM¬O³Ì¦nªº¿ï¾Ü
¦b¥xÆW¶Ò¸ê¤]µLªk¶Ò¨ì¦X²z»ù®æ
¥t¿³ÂdªÑªF¦b¥xÆWªÑ¥÷¤@¯ë¾Þ§@¬yµ{¬O·|´«¦¨®ü¥~±±ªÑ¤½¥q¦A¨ì®ü¥~Listing
¦b¤U¿³Âd«e§¹¥þ¥i¦Û¥Ñ¶R½æ,¤]¨S¦³Å¥¤£À´ªºµ²ºâ°ÝÃD,¤£·Q¤@°_¥h®ü¥~ªº,§¹¥þ¥i³z¹L¥«³õª½±µ½æ¥X,²³æ©úÁA
¿³ÂdªÑ²¼¤£¦üF¤½¥q¤~»Ý©Ó¿Õ¦¬ÁʪѲ¼, ¥»°ê¿³Âd¤½¥q§K,
¤]¨S¦³§AÁ¿¤°»òµ²ºâ°ÝÃD
½Ð°Ñ¦Ò www.selaw.com.tw/LawArticle.aspx?LawID=G0100713
½Ð¬d©ú¦A»¡,¨Ã½Ð§iª¾ªk±ø
¤ß®®¨«¤J°ê»Ú¤Æ¡A¥u¦³¤@Ó¤è¦V¹ï¤pªÑªF¦³§Q¡A¨º´N¬O¥~¸ê§ë¸ê¡C
Y¬O¨ì°ê¥~¥h¤W¥«¡A°ò¥»¤W®Ú¾Ú§ÚÃÒ¨÷ªB¤Íªº§iª¾¡A´N¬O¤âÀYªÑ²¼·|³Qµ²ºâ¡A
Áö»¡¿³ÂdªÑ²¼ªºµ²ºâ¡A·|¦³¤½«H¤Oªº·|pµ²ºâ¡A²z½×¤W ¤£·|¦³·l¥¢¡A¦ý¹ê»Ú©O?
§ÚÓ¤Hı±o¨º¥i·l¥¢¤j¤F¡C
¯à§ë¸ê¤ß®®¨Ã«ù¦³ªÑ²¼¨â¦~¦h¸ü¡Anªºµ´¹ï¤£¬O¥h°ê¥~¤W¥«³oºØµ²ªG¡C
¦ýµL½×µ²ªG¦p¦ó¡A¤Ï¥¿§Ú¤]®³¤£¥X100»õ¥X¨Ó§ë¸ê¡A©Ò¥H¤pªÑªF¤]¥u¯à»{©R»{¤À¡A¤j·§¬O³o¼Ë....ü
¦Ü©ó¬Fªv¤O¤¶¤Jµ¥µ¥¡A¤]§O·Q¤Ó¦h¡A³o¸Ìªº°Q½×¡A¼vÅT¤O¨S¨º»ò¤j....XD
Tau³J¥Õªº¥\¯à ¥i¯à¬OÅý¯«¸g¤¸«O«ù·LºÞ¥Íªø°ÊºA
¨Ó·½¡G¾Ç³N¸g½n ¡@2018-07-02
med.sina.com/article_detail_103_1_48281.html
¦b¥D¬yÆ[ÂI¤¤¡A¬ì¾Ç®a̬۫HTau³J¥Õ¯à¦b¸£²ÓM¤¤°_¨ìéw·LºÞ¡]¤@ºØ²ÓM°©¬[¡^ªº§@¥Î¡C¦ýªñ¤éµoªí¦b¡m²ÓM¡n¥Xª©ªÀºX¤U¡mCurrent Biology¡n¤Wªº¤@¶µ¬ã¨s¡A«h¦³±æÄAÂгoÓÆ[ÂI¡CµØ¤H¾ÇªÌLiang Qiang³Õ¤h¦@¦P¥D¾Éªº¤@¶µ¬ã¨sªí©ú¡ATau³J¥Õªº¥\¯à¥i¯à«ê«ê¬Û¤Ï¡X¡X¦b¯«¸g¤¸¨½¡A¥¦ªº¹ê»Ú¥\¯à¬O«O«ù·LºÞ¥Íªø°ÊºA¡A¦Ó¤£¬OÅý¥¦Ìéw¡C
¡§¥D¬yÆ[ÂI»{¬°¡A¯«¸g°h¦æ©Ê¯e¯fªº±wªÌ¡A¤§©Ò¥H·LºÞ·|¥¢¥h§@¥Î¡Aì¦]¦b©ó¥¦ÌÅܱo§ó¤£Ã©w¡C¦ý§Ú̪º¬ã¨sªí©ú¡A¯Ê¥FTau³J¥Õ«á¡A±wªÌ¯Ê¤Öªº¨ä¹ê¬O·LºÞªº°ÊºA°Ï°ì¡A¡¨¸Ó¬ã¨sªº¦@¦P³q°T§@ªÌPeter Baas³Õ¤h»¡¹D¡G¡§¦]¦¹¡A¦pªG¥Îéw·LºÞªºÃĪ«¥hªvÀø¯«¸g°h¦æ©Ê¯e¯f¡A¥i¯à·|¾A±o¨ä¤Ï¡C¡¨
¦b³o¶µ¬ã¨s¸Ì¡A¬ì¾Ç®a̲M°£¤F¤p¹«¯«¸g¤¸¨½ªºTau³J¥Õ¡AµM«á¤ñ¸û¶b¬ð¤¤ªº·LºÞ¤ô¥¡C¥L̵o²{¡A¾¨ºÞ¶b¬ð¸Ìªº·LºÞ¶q¦³©Ò¤U°¡A¦ý³o¨Ã«D¥Ñ©ó¥¦ÌÅܱo¤£Ã©w¡C¬Û¤Ï¡A³o¬O¥Ñ©ó·LºÞªº°ÊºA°Ï°ìÅܤ֤F¡C¦Ó¥B¡A·í¯«¸g¤¸¯Ê¥FTau³J¥Õ®É¡A¥¦Ìªº·LºÞ¹ê»Ú¤W¤Ï¦ÓÅܱo§óéw¤F¡C³oÓµo²{¨ê·s¤F§ÚÌ´X¤Q¦~¨Ó¹ïTau³J¥Õªº»{ª¾¡C
¤U¤@¨B¡A¬ì¾Ç®aÌ´Á«Ý¦b¨ä¥L°Êª«¼Ò«¬¤¤ÀËÅç¥L̪ºµo²{¯à§_±o¨ì«½Æ¡C¦pªG³oÓµo²{¨ã¦³´¶¹M©Ê¡A¨º¹ï©óªü¯÷®üÀq¯fµ¥¯«¸g°h¦æ©Êªº¯e¯f¦Ó¨¥¡A¥i¯à±a¨ÓªvÀø¤è®×ªº²·s¡X¡X¥¦ªí©ú¥Ø«eÁ{§É¸ÕÅ礤¥Î©óéw·LºÞªºÃĪ«¡A¥i¯à¤£·|°_®Ä¡C
¤£¤[«e¡A§Ú̳ø¾É¤F¯f¬r·P¬V»Pªü¯÷®üÀq¯f¤§¶¡ªº¼ç¦bÁpô¡C¦ÓÃö©óTau³J¥Õªº³o¶µ¬ã¨s¡A¤]¦P¼ËÅý§ÚÌ«¼f¹L¥hªº»{ª¾¬O§_¥¿½T¡C³Ìªñ¡Aªü¯÷®üÀq¯f¬ãµo»â°ì¨ú±o¤F¤@¨t¦C®À§é¡C¤£¯}¤£¥ß¡A¤]³\¡A§Ú̬O®ÉÔ¦^¨ì¹êÅç«Ç¡A§ó²`¤J¦a¥h¤F¸Ñ³oºØ¯e¯f¤F¡C
¨Ó·½¡GÃÄ©ú±d¼w¡@2018-07-02
med.sina.com/article_detail_103_2_48265.html
¤¤¼Ï¯«¸g¨t²Î¯e¯f
ÃĪ«¦WºÙ¡GAimovig¡]erenumab-aooe¡^
¬ãµo¤½¥q¡G¦w¶i¡]Amgen¡^
¾AÀ³¯g¡G°¾ÀYµh¹w¨¾
§åãÃþ«¬¡Gº¦¸§åã
¦b3´ÁÁ{§É¸ÕÅç¬ã¨sªº³Ì«á¥|©P¡]²Ä9-12¶g¡^¡A¨C¤ë°¾ÀYµh¤Ñ¼Æ¤ñ°ò½u¦Ü¤Ö´î¤Ö50%ªº±wªÌ¤ñ¨Ò¹F¨ì¤F¥Dn²×ÂI¡Cȱo¤@´£ªº¬O¡AAimovig¬OFDA§å㪺²Ä¤@Ó¹w¨¾©Ê°¾ÀYµhªvÀøÃĪ«¡C
ÃĪ«¦WºÙ¡GGilenya¡]fingolimod¡^
¬ãµo¤½¥q¡G¿ÕµØ¡]Novartis¡^
¾AÀ³¯g¡G¦hµo©Êµw¤Æ¯g
§åãÃþ«¬¡GÂX¤j¾AÀ³¯g
Á{§É¸ÕÅç¬ã¨sµ²ªGªí©ú¡A¦bªvÀøªº¨â¦~«á¡AGilenya²Õªº¨àµ£±wªÌ¦³86%¨S¦³¥X²{¯gª¬´_µo¡A³o¤@¼Æ¦r¦b¹ï·Ó²Õ¤¤¶È¬°46%¡C°ò©ó³o¤@¥X¦âªº¦¨ªG¡A³o´Ú·sÃĦb·s¾AÀ³¯gªºªvÀø¤W´¿Àò¬ð¯}©ÊÀøªk»{©w©MÀu¥ý¼fµû¸ê®æ¡C³o¬O¬ü°êFDA§å㪺º´Ú¨àµ£¦hµo©Êµw¤Æ¯g·sÃÄ¡C
ÃĪ«¦WºÙ¡GBRIVIACT®¡]brivaracetam, ¥¬¤O¦è©Z¡^
¬ãµo¤½¥q¡GUCB
¾AÀ³¯g¡GÅöíw
§åãÃþ«¬¡GÂX¤j¾AÀ³¯g
¬ü°êFDA¤w¸g§åã¤F¸Ó¤½¥q³Ì·sªº§ÜÅöíwÃĪ«BRIVIACT®¡]brivaracetam¡A¥¬¤O¦è©Z¡^¤fªA»s¾¯ªº¸É¥R·sÃĥӽС]sNDA)¡A¥Î©ó³æ¿W©Î»²§UªvÀø4·³¤Î¥H¤W±wªÌªº§½³¡Åöíwµo§@¡]partial-onset seizure¡APOS¡^¡C¦¹«e¡AFDA´¿§åãBRIVIACT®¥Î©ó³æ¿W©Î»²§UªvÀø16·³¤Î¥H¤W±wªÌªºPOS¡C
¤Í¤Í¤j
¤p©¯¹B¤j
®ÇÆ[ªÌ¤j
jm0423 ¤j ªº¤À¨É¹ªÀy
¤×¨ä ¤Í¤Í¤j ¥H¨äÂå¾Ç±M·~Æ[ÂI¤À¨É¤ß±o Åý§Ú̧ó¶}ÂX²´¬É ·PÁ±z!
¨â«h·s®öºôªº·s»D
FDA§åãNuplazid½¦Ån¾¯©M10mg¤ù¾¯¤W¥« ªvÀø¤Ûı©M¦k·Q
¨Ó·½¡G ¥Íª«¨¦ ¡@2018-07-01
med.sina.com/article_detail_100_1_48242.html
¬ü°ê¥Íª«»sÃĤ½¥qAcadia Pharmaceuticalsªñ¤é«Å¥¬¡A¬ü°êFDA¤w§åã¤F©¬ª÷´ËÃĪ«Nuplazid¡]pimavanserin¡^ªº¤@ºØ·sªº½¦Ån¾¯«¬¡]34mg¡^©M¤@ºØ·sªº¤ù¾¯¾¯¶q¡]10mg¡^¡A¥Î©óÀ°§U±wªÌªvÀø©¬ª÷´Ë¯f¡]PD¡^¬ÛÃöªº¤Ûı©M¦k·Qµ¥ºë¯«¯gª¬¡C34mg Nuplazid½¦Ån¾¯©M10mg¤ù¾¯±N©ó8¤ë¤¤¦¯¦b¬ü°ê¤W¥«
¦b¬ü°ê¡ANuplazid©ó2016¦~5¤ëÀòFDA§åã¤W¥«¡A¦¨¬°ºÓÀò§åªvÀøPD±wªÌ©Ò¸g¾ú¤Ûı©M¦k·Qµ¥ºë¯«¯gª¬ªºÃĪ«¡CNuplazidªºÀò§å¡A¼Ð»xµÛ©¬ª÷´Ë¯f©Êºë¯«¯fÁ{§ÉªvÀøªº«¤j¨½µ{¸O¡C¤§«e¡AFDA¤w©ó2014¦~±Â¤©Nuplazid¬ð¯}©ÊÃĪ«¸ê®æ¡C
¦bÁ{§É¬ã¨s¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡ANuplazidÅãµÛ°§C¤Fºë¯«¯f¯gª¬ªºµo¯fÀW²v©MÄY«µ{«×¡A¦P®É¥¼·l®`¹B°Ê¥\¯à¡C·~¬É¹ïNuplazidªº°Ó·~«e´º¤]¤Q¤À¬Ý¦n¡AEvaluate Pharma¹wp¸ÓÃĦb2020¦~ªº¾P°âÃB±N¹F¨ì8.41»õ¬ü¤¸¡A¥t¦³¤ÀªR®v¹wpNuplazid±N¦b5¦~¤º¦¨¬°¦~¾P10»õ¬ü¤¸ªº«½SÃĪ«¡C
¤T®a¥Íª«¥ø·~u´ä¤W¥« ´ä¥æ©ÒP¤O¥´³y¥Íª«¬ì§Þ¥Dn¸ê¥»¥«³õ
¨Ó·½¡G°·±d¬É ¡@2018-07-01
§@ªÌ¡G¶qÄ_
med.sina.com/article_detail_100_2_48224.html
¤è¹FÂåÃĬO¼Æ¤é¤ºu´ä¤W¥«ªº²Ä¤T®a¥Íª«¥ø·~¡C6¤ë28¤é¡AÄ~·ù¬ìÂåÃÄ¥¿¦¡¦V´ä¥æ©Ò´£¥æ¤W¥«¥Ó½Ð¤§«á¡A¦¹«e´¿¶Ç¥X±ó¬üu´ä¤W¥«ªº¸~½FÃĪ«¬ãµo¥ø·~«H¹F¥Íª«¤]¥¿¦¡«Å¥¬¤Fu´ä¤W¥«®ø®§¡C
³o¤T®a¤½¥q³£ÄÝ©ó¥Íª«ÃÄ¥ø¡AP¤O©ó·sÃĬãµoªº·ù¬ìÂåÃÄ©M«H¹F¥Íª«¨ÃµL°Ó«~¤Æ¥ô¦ó²£«~¡A¦]¦¹¨S¦³¥ô¦ó¦¬¯q¡C
´ä¥æ©ÒªºÁ|±¹¬°¥»¤w¸g¼ö¤õªº¥Íª«ÂåÃĦæ·~¼W²K¤F¼ö«×¡C¥¦w³Ð§ë¸³¨ÆÁ`¸g²z±i¦¿ªí¥Ü¡A©úÅã·Pı¨ì¥Íª«¬ì§ÞÀY³¡¤½¥q¦ôȤôº¦²î°ª¡A¡§¤µ¦~¥X²{¤F¦hÓ¦ôÈ30»õ¬ü¤¸¥H¤Wªº¤½¥q¡A¤£ºÞA½üÁÙ¬OB½ü¡A³£»¡¦Û¤v¬OPre-IPO½ü¡C¡¨
¾Ú°·±d¬É²Îp¡A¥Ø«e¤w¸gu´ä¤W¥«ªº¥Íª«¥ø·~¦³ºq§ÃÄ·~¡B¦¨¤j¥Íª«¡BµØ»âÂåÃĵ¥¡C¤µ¦~¥i¯àu´ä¤W¥«ªº¥Íª«¬ì§Þ¥ø·~ÁÙ¦³´_§»º~ÀM¡B¤W®ü¤Ñ¤h¤OÃÄ·~¡B¥Ã®õ¥Íª«¡B·LÂ嶰¹Î¡B°·¯à¶©¡B«eªu¥Íª«¡B¶}©ÝÃÄ·~¡B¿Õº¸±dµ¥¡C
¥Í§Þ·sÃĤ½¥q¦³§V¤OªÑ»ù¦Û·|ªíºA..@¤ßµ¥
²£«~¦³µ²ªG¯àÀò§Q¤~¬O¯u¹ê¤O...¥~¦b®ø®§
³£¬O°²¶H..¤@¯ëªù¥~º~¤Ö¤JÀ¸¤Ó²`¨ü¶Ë¸û¤p
·í¯¸¤W¦~½u·Q¹³¬O¤½¥q§V¤O¥X½u¾÷·|¨ÓÁ{
´²¤á¦ÊªÑ°Ñ»P¤]¥i¼Ö¦b¨ä¤¤
ºë¯«¯fÃĬO²{¥NªÀ·|»Ý¨D²£«~¡A´Á«Ý¤½¥q§V¤O¡A¤Ï«äÃĪ«¥i½w¸Ñ¡A¤£¬O¯u¸ÑÃÄ.
³o¬O¦³¥h°Ñ¥[ªÑªF·|ªººÖ§Q...©Ô¦^¥¿¦n¥[½X¶R...¸`¬Ù¤F«Ü¦h¦¨¥»...
©M©¾¹ê¤á¤Î¤jªÑªF¯¸¦b¦P¤@Ãä´N¹ï¤F...
µ¥«Ý¥¼¨Ó¯¸¤W°ê»Ú...¤ñ»ùSAGE...¥¼¨Ó·sÃij°Äò¬ãµo§¹¦¨...¥«È·|¶W¶VSAGE...
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~
³o´X¤Ñ¬Ý¨ì¤F¤j®aªº¤£¦w¡A§Ú·Q§i¶D¤j®a¡A³o¶¡¤½¥q¡A³o´XÁû·sÃÄ¡A¹ï©ó¥þ²yªº¤HÌ¡A¯uªº«D±`«D±`ªº«n¡A§Ú¦bÁ{§É¤W©Ò¹J¨ìªº±wªÌ¡A´N¬O¦bµ¥«ÝµÛ³o¨ÇÃĪº°Ý¥@¡A¤ß®®¤@©w·|¦¨¥\ªº¡A¦Ü¤Ö¥Ø«e§Úªº¤F¸Ñ¬O¶¶§Qªº¡A§Ú̯వªº¥u¬O¶RªÑ²¼¤ä«ù¡A¤j®a¤@°_¬°¤ß®®¥[ªo³á¡I
³¥¤ß
¦Û±þ·N©À
¯«¸g¦A¥Í
Åý¤H¦L¶H²`¨èªº»yµü
·Q¦b½Ð±Ð¤@¤UªÑªF·|¤¤¦³µL´£¨ì¥Ø«e SND-13¦¬®×ªºª¬ªp?´Á¤¤¤ÀªR°µ¤F¶Ü(©Î¬O¹wp¦ó®É¶i¦æ?)
Á{§É¹êÅç¤H¼Æ¦³µL½Õ¾ã?¤Î¦b«áÄòªºOPEN TRAIL¦³µL¬Ý¨ì¬Æ»òÁͶÕ?
·P®¦
½Ð°Ý¦³°Ñ¥[ªº¥ý¶i
¬O§_¦³½Í¤ÎSND-13¦¬®×¶i«×¡H
¤SSNG-12¬O§_·|¥Ó½ÐBTD?
¥t¥~¦Ñ¥v¤j³o¤S¬O«ç»ò¦^¨Æ¡H
Àµ½Ð¨}µ½®®¤Í¼·¤¾¦^ÂÐ
¤@«h¥H¼~¡A¤@«h¥H³ß§r¡I
¤½¥qªº¦U¶µ²£«~¤´«ö³¡´N¯Zªº«e¶i¡A
¼W¸êªº³W¹º¬O¦UºØ¤è®×³£¦³¦Ò¼{¡A®ü¥~©Î°ê¤º³£¬O¿ï¶µ¡A¦~©³§Y¥i´¦¾å¡A
¤ß®®¨ÌµMèB«e¶i¡A¤j®a¥i¥H©ñ¤ß~
YEAH! ¦³®ü¥~IPO!!!
1.ªÑªF·|ÁÙ¨S¶}´N±þ ,¤À©ú¬O¦³¤H·Q¤U¨®,¤£¥Î§ä²z¥Ñ,¸òªÑªF·|µLÃö
2.¦~©³«e·|¥[¶}ªÑªFÁ{®É·|,°Q½×®ü¥~IPO/¶Ò¸ê¬ÛÃöij®×
3.»¡©ú¦UPipeline¶i«×,±Ð±Â¨ÌµM«H¤ß¤Q¨¬
¥H¤W¨Ñ¤j®a°Ñ¦Ò
¦]¤£§J°Ñ¥[ªÑªF·|
¥i§_¹ï¤µ¤ÑªÑªF²³æ±Ôz¤@¤U
ÁÂÁÂ
n¤U¨®ªº§Ö¤U¨®§a
[ Major depressive disorder with suicidal ideation ]
²³ø P.44
www.bplifescience.com/SyneuRxPresentationApril2018.pdf
§ÚÌ¥H«e½Í¹L Æ{§í¯g»â°ìªºBTD , ¾AÀ³¯g¦U¦³¤£¦P
esketamine : ( »óµÄµ¹ÃÄ )
Àò BTD ®É¶¡ : 2013/11
¾AÀ³¯g : treatment-resistant depression
esketamine :
Àò BTD ®É¶¡ : 2016/08
¾AÀ³¯g :major depressive disorder with imminent risk for suicide.(ÄY«§íÆ{¯g¨Ã¦³§Y±Nµo¥Íªº¦Û±þ·ÀI)
Rapastinel : ( NMDA receptor partial agonist ) ÀR¯ßµ¹ÃÄ
Àò BTD ®É¶¡ : 2016/01
¾AÀ³¯g : Adjunctive Treatment of Major Depressive Disorder (MDD)
SAGE-547 : ( GABA modulator ) ÀR¯ßµ¹ÃÄ
Àò BTD ®É¶¡ : 2016/09
¾AÀ³¯g : ªvÀø²£«á§íÆ{¯g¡]PPD¡^
SAGE-217 : ( GABA modulator ) ¤fªA
Àò BTD ®É¶¡ : 2018/02
¾AÀ³¯g :the treatment of major depressive disorder (MDD)
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¨Ó·½¡G ¥Íª«¨¦ ¡@2018-06-26
med.sina.com/article_detail_103_1_47987.html
^°ê»sÃĤ½¥qGW Pharma¬O´Óª«·½©Ê¤j³Â¯ÀªvÀø²£«~¬ãµo»â°ìªº¥þ²y»â¾ÉªÌ¡AP¤O©ó±q¤j³Â¤¤µo²{¡B¶}µo¡B°Ó·~¤Æ·s«¬ªvÀøÃĪ«¡Cªñ¤é¡A¸Ó¤½¥q«Å¥¬¡A¬ü°êFDA¤w§åã¤j³Â¯ÀÃĪ«¡X¡XEpidiolex¡]cannabidiol¡A¤j³Â¤G¾J¡^¤fªA²GÅé»s¾¯¡A¥Î©ó2·³¤Î¥H¤W±wªÌ¡A»²§UªvÀø»PLennox-Gastautºî¦X¼x¡]LGS¡^©MDravetºî¦X¼x¡]DS¡^¬ÛÃöªºÅöíw¡Cȱo¤@´£ªº¬O¡A¦¹¦¸§åã¡A¨ÏEpidiolex¦¨¬°ºÓ°ª¯Â«×¡B´Óª«·½©Ê¤j³Â¤G¾J¡]CBD¡^³B¤èÃĪ«»s¾¯¡A¦P®É¤]¬OºÓ·s«¬§ÜÅöíwÃĪ«¡]AED¡^¡C
GW¹wp¡A±N¦b¥¼¨Ó3Ó¤ë±NEpidiolex±À¦V¬ü°ê¥«³õ¡C·~¬É¹ïEpidiolexªº°Ó·~«e´º¤]¤Q¤À¬Ý¦n¡A¤µ¦~¦~ªì¡A¬ìºÍ°ß¦wµo¥¬³ø§i¹w´ú¡AEpidiolex¦b2022¦~ªº¾P°âÃB±N¹F¨ì12»õ¬ü¤¸¡C
Epidiolex»²§UªvÀøLGS©MDS¬ÛÃöÅöíwªºÀò§å¡A¬O°ò©ó3ÓIII´Á¦w¥þ©Ê©M¦³®Ä©Ê¬ã¨sªº¼Æ¾Ú¡A¨C¤@Ó¬ã¨s³£¹F¨ì¤F¥Dn²×ÂI¡C³o¨Ç¬ã¨s¤¤¡AEpidiolexªº¤@¯ë@¨ü©Ê¨}¦n¡CEpidiolex NDA¤¤¥]¬A¤j¬ù1500¨Ò±wªÌªº¦w¥þ¼Æ¾Ú¡A¥H¤Î¤j¬ù400¨Ò±wªÌ³sÄòªvÀø1¦~¥H¤Wªº¼Æ¾Ú¡C
Lennox-Gastautºî¦X¼x¡]LGS¡^¡A¬O¤@ºØ»P¦~ÄÖ¦³ÃöªºÁô·½©Ê©Î¯gª¬©Ê¥þ¨©ÊÅöíwºî¦X¼x¡A§Y¦~Ä֨̿à©ÊÅöíw©Ê¸£¯fªº¤@ºØÃþ«¬¡C¨ä¯SÂI¬°µo¯f¦~ÄÖ¦¡A¥®¨à®É´Á°_¯f¡Aµo§@§Î¦¡¦h¼Ë¡A´¼¤Oµo¨|¨ü¼vÅT¡AªvÀø¸û§xÃø¡C¬O¤@ºØÄY«ªºÅöíwÃþ«¬¡C
Dravetºî¦X¼x¡]Dravet syndrome¡ADS¡^¤SºÙÀ¦¨àÄY«¦Ù°}ÅË©ÊÅöíw¡A¬O¤@ºØ¤Ö¨£ªº¥Dn¥Ñ¿ò¶Ç¦]¯À¤Þ°_ªº¶i¦æ©ÊÅöíw©Ê¸£¯f¡A¨ã¦³µo¯f¦~ÄÖ¦¡Aµo§@Ãþ«¬¦h¼Ë¡Aµo§@ÀW²v°ª¡A´¼¯à·l®`ÄY«¡AÃĪ«ªvÀø®ÄªG®tµ¥¯SÂI¡C¸Ó¯f¹w«á¸û®t¡A´X¥G©Ò¦³±w¨à³£¦³»{ª¾·l¶Ë¡C
Voyager©¬ª÷´Ë¤ó¯g°ò¦]Àøªk ÀòFDA¦A¥ÍÂå¾Ç¥ý¶iÀøªk»{©w¡I
2018/6/22 ¾ã²z/½s¿è³¡
µoªí©ó 2018-06-22 §@ªÌ °OªÌ®}²b
www.gbimonthly.com/2018/06/26799/
¶}µo¯«¸g¯e¯fÀøªkªº¥Íª«Âå¾Ç¤½¥qVoyager Therapeutics¤µ¡]22¡^¤é«Å§G¡A¬ü°êFDA¬°¨äVY-AADC°ò¦]Àøªk¹{¥¬¦A¥ÍÂå¾Ç¥ý¶iÀøªk¡]RMAT¡^»{©w¡A¸Ó»{©w±N¥]¬AFDA§Ö³t³q¹D©M¬ð¯}©ÊÀøªk»{©wªº©Ò¦³Àu¶Õ¡CVY-AADC°ò¦]Àøªk¬°ªvÀøÃø¥H¶i¦æÂå¾ÇºÞ²z¡B¦³ÃĮĪi°Ê¡]motor fluctuations¡^ªº©¬ª÷´Ë¤ó¯g±wªÌ¡C
©¬ª÷´Ë¤ó¯g¬O¤@ºØºC©Ê¯«¸g°h¤Æ©Ê¯e¯f¡A¼vÅT¬ü°ê¬ù100¸U¤H¤f¡A¥þ²y¬ù700-1000¸U¤H¤f¡CÁö¥Ø«e¦h¼Æ©¬ª÷´Ë¤ó¯g±wªÌªº¯f¦]©|¤£²M·¡¡A¦ý¸Ó¯e¯fªº¹B°Ê¯gª¬¬O¥Ñ©ó²£¥Í¯«¸g¶Ç»¼ª«½è¦h¤ÚÓiªº¤¤¸£¯«¸g¤¸¯Ê¥¢©Ò¤Þ°_ªº¡C¥Ø«eÁÙ¨S¦³¯à¦³®Ä´î½w©Î°fÂ੬ª÷´Ë¤ó¯g¶i®iªºÀøªk¡A¥ª±Û¦h¤Ú¤´¬O¸Ó¯e¯fªº¼Ð·ÇªvÀø¤èªk¡C
¨ä¤¤¡A¾Ú¦ôp¡A°ª¹F15%ªº©¬ª÷´Ë¤ó¯g±wªÌ¨ã¦³Ãøªv©ÊÃĮĪi°Ê¡A¥ª±Û¦h¤Ú¤]µLªk¦³®Ä±±¨î¡CÃĮĪi°Ê«ü±wªÌ¹ïªvÀøªº¤ÏÀ³ÅÜ®t¡A¸g¾ú¸ûªø®É¶¡ªº¹B°Ê½wºC©M»øµw¡A¥ÎÃĤ]µLªk¹F¨ì³Ì¨Î®ÄªG¡A¦¹¤@®É´ÁºÙ¬°¡uÃö³¬´Á¡]OFF-time¡^¡v¡CÃĪ«°_®Äªº®É¶¡¡A¤]´N¬O¡u¶}û£´Á¡]ON-time¡^¡v¤]Åܵu¡C¬°³oÃþ±wªÌ´£¨Ñ¦³®Äªº¯e¯f½w¸Ñ¡A¦¨¬°ÂåÃÄ»â°ì«E«Ý¸Ñ¨MªºÃøÃD¡C
¨Ó·½¡GÃÄ©ú±d¼w¡@2018-06-22
med.sina.com/article_detail_103_2_47829.html
¤µ¤é¡A¶}µoªvÀø¯«¸g¯e¯fªº¥Íª«Âå¾Ç¤½¥qVoyager Therapeutics«Å¥¬¡A¬ü°êFDA¬°VY-AADC°ò¦]Àøªk¹{µo¤F¦A¥ÍÂå¾Ç¥ý¶iÀøªk¡]RMAT¡^»{©w¡AªvÀøÃø¥H¶i¦æÂå¾ÇºÞ²z¡A¦³¹B°Êªi°Êªº©¬ª÷´Ë¯f±wªÌ¡C
¦¹¦¸ªºRMAT»{©w¬O¬ü°êFDA®Ú¾Ú³Ìªñ21¥@¬öªv·Uªk®×¡]21st Century Cures Act¡^¡A¥Î©ó«P¶i©M§åã¥]¬A°ò¦]Àøªk¦b¤ºªº¦A¥ÍÂå¾Ç²£«~ªº¥[³tp¹º¡C¸Ó»{©w¥]¬AFDA§Ö³t³q¹D©M¬ð¯}©ÊÀøªk»{©wªº©Ò¦³Àu¶Õ¡A¨Ï¨ä¯à°÷»P¸Ó¾÷ºc¶i¦æ¦´Á¥æ¬y¡A°Q½×´À¥N©Î¤¤´Á²×ÂI¡A¤ä«ù¼ç¦bªº¥[³t§åã¨Ãº¡¨¬§åã«án¨D¡CRMAT»{©w¦®¦bªvÀø¡Aקï¡A°fÂà©Îªv·UÄY«©Î¦M¤Î¥Í©Rªº¯e¯f©Î¯gª¬¡Cªì¨BªºÁ{§ÉÃÒ¾Úªí©ú¡A¸ÓÀøªk¦³¥i¯à¸Ñ¨M³oºØ¯e¯f©Î¯f¯gªº¥¼º¡¨¬ÂåÀø»Ý¨D¡C
¡§RMAT»{©w¬O°ò©ó§ÚÌVY-AADCªº1b´ÁÁ{§É¼Æ¾Ú¡A¨Ã¥B¥Nªí¤F¦¹¶µ°ò¦]Àøªk§@¬°©¬ª÷´Ë¯f¼ç¦bªvÀø¤è®×ªº¤@Ó«n¨½µ{¸O¡A¡¨ VoyagerªººÊºÞ¨Æ°È©M½è¶q«OÃÒ°ÆÁ`µôRobert Pietrusko³Õ¤h»¡¡G¡§§ÚÌ´Á±æ³q¹LRMAT»{©w»PºÊºÞ¾÷ºc±K¤Á¦X§@¡A¬°VY-AADCªº¶}µo´£¨Ñ«ü¾É¡A¥]¬A´£¨Ñ«Øij¥H«K¦³®Ä¦a¤ä«ù³o´ÚÃĪ«Àò±o§åã¡C¡¨
¬Ý¨ì¬Y¤jªÑªF«ùªÑ¼Wªñ2000±i~
Ãø©Ç³Ìªñ¶i¥Xªí¬Ý¨ì·í¦a¨é°Ó¤@ª½¶R¶i!
¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-06-21
med.sina.com/article_detail_103_2_47718.html
3. Biogen ªºªüº¸¯ý®üÀq¯g¹v¦V£]¾ý¯»¼Ë´³¶ôÔ¿ï·sÃÄ Aducanumab ³º»®µM¦b¦C , EvaluatePharmaÁÙ¦ô¨ä²{Ȧb 84»õ¬ü¤¸ ¥ª¥k
ÁöµM¬Û¦ü§@¥Î¾÷¨îªºÃĪ«±µ³s¥¢±Ñ¡A¦ýEvaluatePharma¨Ì»{¬°¡A¦Ê°·ªºªüº¸¯ý®üÀq¯fÔ¿ïÃĪ«aducanumabªº²{Ȧb 84»õ¬ü¤¸ ¥ª¥k¡A¦P®É¤@¥¹¤½¥q¦b2020¦~ªì¤½§G¶i¦æ¤¤ÃöÁäÁ{§É¸ÕÅ窺µ²ªG³o¤@¼Æ¦rÁÙ±N¤j´T¤W¤É©Î¤U°¡C
¦b¤@¶µ¬Û¹ï¸û¤pªº¬ã¨s¤¤¡A¬ã¨s¤Hûª`·N¨ì¨Ï¥ÎaducanumabªvÀø²Õªº±wªÌ¦bÁ{§Éè§b´ú¸Õ¤¤ªºªí²{¤U°¸û¤Ö¡A¾¨ºÞ³o¨Ç®t²§¤£¨¬¥H³Q»{¬°¨ã¦³²Îp¾Ç·N¸q¡C¶È¦b¬ü°ê¡AÁÙ¨S¦³¥ô¦ó¤èªk¥i¥H´î½w³oºØ¼vÅT570¸U¤H¯e¯fªº¶i®i¡C¦pªG¦Ê°·ªºÔ¿ïÃĪ«¯à°÷¦b§ó¤jªº¸ÕÅ礤±o¨ìÃÒ©ú¡A±N¥i¯à¦¨¬°§óºZ¾PªºÃĪ«¡C
¥xÁÞ¤jªº¹ªÀy
¤Óºò±i¤jªº¤À¨É
¤p§Ì¤]¥u¬OÂà¶K¦bºô¤W§ä¨ìªº¸ê®Æ¡A¶È¬°Á|¤â¤§³Ò¦Ó¤w
§Æ±æ¥xÆWªº¥Í§ÞªÑ³£¯à§ä¨ì¦Û¤vªº©w¦ì©M§Q°ò¡A¦b¥«³õ¦û¦³¤@®u¤§¦a
®É¶¡¾÷¹B¨ì¤F¡A¦ÛµM·|´²µo¦Û¨À³¦³ªº¹ê¤O©M¥ú±m
¥xÆW¥Í§Þ¥[ªo¡I
ÁÂÁ¤j®a¡I
²q·Q¤j§V¤O¬ã¨s¨D¯uªººë¯«¬O¤j®a¾Ç²ßªº¨å½d¡A´Á¬ß©Ò¦³¥xÆW¥Í§ÞÂåÃĪѤ¤¦³¼ç¤OªºªÑ²¼³£¤@Àɤ@ÀɯàÀò±oÀ³¦³ªº»ùÈ¡C
¥xÆW¦Y§Ü¼~Æ{ÃĦѤH¤ñ¨Ò¼W¦Ü12.2%
´«ºâ¬ù40.28¸U¦Ñ¤HªA¥Î ¥@½Ã²Õ´¡]¢å¢Ö¢Ý¡^§ó¦ôp¡A¼~Æ{¯g¤G¡³¤T¡³¦~±N¦¨¬°¯e¯ft¾á²Ä¤@¦ì
µØµø·s»D 2018/06/19
news.cts.com.tw/cts/general/201806/201806191928807.html
2018-06-19 00:02¸gÀÙ¤é³ø ¤ý©É´@
udn.com/news/story/7485/3205553?from=udn_ch2cate6644sub7485_pulldownmenu
¤µ¦~4¤ë9¤é¡A©¬ª÷´Ë¤ó¯g¡]Parkinson¡¦s Disease¡A²ºÙPD¡^CNN³ø¾É¡A2016¦~¥H¬ð¯}©ÊÀøªk³QFDA®Öã¡A¦¨¬°²Ä¤@ÓªvÀøPD©Ò¾ÉP¤Ûı¯gª¬ªº·sÃÄ-NUPLAZID (pimavanserin)¡A¦b¤W¥«¤£¨ì¥b¦~ªº´Á¶¡¡A³º³y¦¨244¦ì±wªÌ¦º¤`¡A¦º¤`²v°ª¹F10.9%¡C
³o®ø®§Åý¨ä¥À¤½¥qAcadia PharmaceuticalsªºªÑ»ù·í¤é«³Ð22%¡A³Ì«áFDA¨u¨£ªº¦b¨ä¥é³æ¤W¡A¥[µù¶H¼x¦MÀI©Ê¯Å§O³Ì°ªªº¶Â®Øĵ»y¡]black box warning¡^¡A¨Ã¨M©w¹ïNUPLAZID«±Ò¦w¥þ¼f¬d¡C
...
ªñ¦~¨Ó¡A¯«¸g°h¤Æ©Ê¯e¯fªºÃĪ«¶}µo¥¢±Ñ¤w¬O±`ºA¡AÃĬɥ¨ÀY¤]¤£·Qª±¤F
±¹ï±µ³sªº¥¢±Ñ¡A¬ì¾Ç¬É¤]¶}©l±´´M¨ä¥LªºªvÀø¤è¦V¡A¨ä¤¤¸z¹Dµß´N¬O³Ì¨ã§Æ±æªº¤è¦V¤§¤@¡C2013¦~¡A¥[¦{²z¤u¾Ç°|ªºSarkis Mazmanian±Ð±Â¡Aº¦¸©ó¡mCell¡n´Á¥Zµoªí¤F¸z¹Dµß·|¼vÅT¸£³¡¬¡°Ê¡A¨Ã»P¼~Æ{¡B¦Û³¬¯g¡B¤Î¸£¯«¸g¯e¯f¬ÛÃö¡C¬ì¾Ç®aµo²{¡A¸z¹D²Óµß¥iÂǥѤº¤Àªc¤è¦¡»P¤j¸£¥æ¬y¡A±±¨î¸z¹D¦åºÞ¤Î¦å¸£»ÙÂzªº³q³z©Ê¡A¶i¦Ó¥æ´¥X©Ò¿×ªº¡u¸z¸£¶b¡v½u¡]gut-brain axis¡^¡C¦b°Êª«¹êÅ礤ÃÒ¹ê¡AÂǥѸz¹D·L¥ÍºA¯à§ïµ½ªü¯÷®üÀq¯g¡B©¬ª÷´Ë¤ó¯g¡B¦hµo©Êµw¤Æ¯g»Pº¥á¯gµ¥¦hºØ°h¤Æ©Ê¯«¸g¯e¯f¯fÄp¡C
¯«¸g°h¤Æ©Ê¯e¯f¤w¬O¥þ²y³ÌÃe¤jªº¥¼º¡¨¬¥«³õ¡A²´¤UFDA»PEMA¤]³£ºÉ¤O©ñ¼e¬ÛÃö·sÃĪºn¨D¡A¦Ó¥ý´Á¬ã¨s§ó¯É¯ÉÃÒ¹ê¥Ñ¡u¸z¸£¶b¡vµÛ¤â¡A¬O°Æ§@¥Î³Ì¤p¡B¥i¦æ©Ê³Ì°ªªº¤è¦¡¡C¤Ñ®É¡B¦a§Q¡B¤H©M¤wµM»ô³Æ¡A¥xÆW¬F©²»P¥ø·~À³¿n·¥¤Á¤J¡A§â´¤¦í¤U¤@¥@¥NÃĪ«°Ó¾÷ªº¦P®É¡A¤]³yºÖ¼s¤j±wªÌ¡C
¡]§@ªÌ¬OÆp¥Û¥Í§Þ§ë¸ê¤ÀªR«Ç¤ÀªR®v¡^
2018-06-12
www.roc-taiwan.org/uslax/post/17668.html
¤ß®®¥ÍÂå³Ð¿ì¤HUCLAÂå¾Ç°|ºë¯«¬ì±Ð±Â½²ªG¯þ¡B«n¥[¤j±Ð±Â§d¶®¬Â¤Ò°ü³X°ÝLA¬ì§Þ²Õ¡A¤¤¤È¥Ñ±i´®i²Õªø°º³\Y»ö¯µ®Ñ³¦P¡A»P¸g¤å³B¦¶¤å²»³BªøÀ\±Ô¥æ´«·N¨£¡C
www.bplifescience.com/SyneuRxPresentationApril2018.pdf ]
P.23
Existing therapies have a mean effect size~=0.3 (total score).
SND-13ªºÁ{§É³]p ES ¬O¥Î¤ñ²{¦æªvÀø¥§¡ÈÁÙ¦nªº >=0.5 ( Power >= 85 % )
¦Ó2aÁ{§ÉªºES ¼Æ¾Ú¬O 1.53
³o¬OÁ{§É¥D«ÈÆ[±ø¥ó¤£¤@ªº¦w¥þ¾l¸Î¶Ü?
½²±Ð±Â§â¦ÒÃD³]pªº©³½u³£±È¶}¤F ? SND-13 ¤S·|µª±o«ç¼Ë©O ?
ªÑªF·|±N©¡ ¤pªº³Ì·Q½Ð±Ð½²±Ð±Âªº¨Æ
·íµMÂ÷¤£¶}Á{§Éªº¶i®i°ÝÃD ¤×¨ä¬OSND-13
¤£ª¾½²±Ð±Â¬O§_Ä@·N³zÅSresponderªºÁ`¼Æ? ¤Î¨ä¦ûÁ`Åé¤ñ¨Ò¦p¦ó? ¤À¥¬ª¬ªp? ÁÙ¦³open label¶¥¬qªº¦¨®Ä?
¨ÌÁ{§Éºôªº¸ê®Æ , §P§OÅãµÛ»P§_ , ¥Îªº¬Ototal score¤À¥¬ªº¼Æ¾Ú, ¦Ó¤£¬O¬Ý¦³µLresponder¤G¤Àªk¨Ópºâ
°Ýresponderªº¤H¼Æ©Î¥i²¤²qÃĮĪº¯à¶q?
¤pªº¤£¤~ , ¦³½Ð¤j®a¿ãÅDµ¹¤©«ü¾É «ü¥¿
ÁÂÁ¤j®a!
¨Ó·½¡GÃÄ©ú±d¼w¡@2018-06-17
med.sina.com/article_detail_103_2_47527.html
ºë¯«¤Àµõ¯g¡]schizophrenia¡^¬O¤@ºØ¥H²§±`ªÀ·|¦æ¬°©M¤£¤F¸Ñ²{¹ê¬°¯S¼xªººë¯«»Ùê¡Cºë¯«¤Àµõ¯g±wªÌ¥i¯à·|¥X²{¤Ûı¡]¤j³¡¤À¬O¤ÛÅ¥¡^¡A¦k·Q¡]±`±`¬O©_²§ªº©Î¢®`ªº¡^¡A«äºû©M¨¥»y²V¶Ã¡Cºë¯«¤Àµõ¯g±wªÌ¸g±`¦³ÃB¥~ªº¤ß²z°·±d°ÝÃD¡A¦pµJ¼{¡A§íÆ{©ÎÃĪ«¨Ï¥Î»Ùê¡C¯gª¬³q±`³vº¥¥X²{¡A±q«C¬K´Á¶}©l¡A«ùÄò«Üªø®É¶¡¡C
ºë¯«¤Àµõ¯g¤j¬ù¦b¥þ²y½d³ò¤º¼vÅT2400¸U¤H¡C¥@¬É½Ã¥Í²Õ´2000¦~ªº¼Æ¾ÚÅã¥Ü¡Aºë¯«¤Àµõ¯gªº¥þ²y±w¯f²v±µªñ1%¡A¨C10000¤H¤¤¬ù¦³1.5¤Hµo¯f¡C¨k©Êµo¥Í²v¤ñ¤k©Ê°ª1.4¿¡A¨Ã¥B³q±`¨k©Ê§ó¦¥X²{¡X¡Xµo¯f°ª®p¦~ÄÖ¨k©Ê¬°25·³¡A¤k©Ê¬°27·³¡C
ºë¯«¤Àµõ¯gªº¥DnªvÀø¤èªk¬O§Üºë¯«¯fÃĪ«ªvÀø¡A³q±`µ²¦X¤ß²zªvÀø©MªÀ·|¤ä«ù¡C¨ä¤¤¤@½uªvÀø¬O§Üºë¯«¯fÃĪ«¡AÃĪ«¥i¥H¦b7¨ì14¤Ñ¤º´î¤Öºë¯«¯fªº¶§©Ê¯gª¬¡CµM¦Ó¡A§Üºë¯«¯fÃĤ£¯àÅãµÛ§ïµ½³±©Ê¯gª¬©M»{ª¾¥\¯à»Ùê¡C®òÁD¥²§Q¡A¶ø´á¥¡A§Q°öଡA©M´â´á¥¬O±`¨£ªººë¯«¤Àµõ¯gÃĪ«¡C
ºI¤î2018¦~5¤ë31¤é¡Aºë¯«¤Àµõ¯g»â°ì¦@¦³108¶µ·sÃÄÁ{§É¸ÕÅç¬ã¨s
ºë¯«¤Àµõ¯g·sÃĪºÁ{§É¸ÕÅç¬ã¨s¶°¤¤¦b¬ü°ê¡A¬ü°ê¦³73¶µ¸ÕÅç
¥þ²y¥Dn¬ã¨sºë¯«¤Àµõ¯g·sÃĪº¤½¥q¬O¡G
Alkermes¡]5¶µ¡^¡A
ACADIA¡]5¶µ¡^¡A
Otsuka¡]4¶µ¡^¡A
Sunovion¡]4¶µ¡^¡A
SyneuRx¡]3¶µ¡^¡A
Lundbeck¡]3¶µ¡^¡A
Boehringer Ingelheim¡] 3¶µ¡^¡A
Takeda¡]2¶µ¡^¡A
Brian Miller¡]2¶µ¡^¡A
Iris Sommer¡]2¶µ¡^¡A
Rovi¡]2¶µ¡^¡A
Sumitomo Dainippon Pharma Co., Ltd.¡]2¶µ¡^¡A
Braeburn¡]2¶µ¡^¡AMarinus ¡]2¶µ¡^¡A
Millennium¡]1¶µ¡^¡A
Roche¡]1¶µ¡^¡C
Understanding Statistical Power and Significance Testing---an interactive visualization
rpsychologist.com/d3/NHST/
Type I and Type II errors, £\, £] , p-values, power and effect sizes ¡V the ritual of null hypothesis significance testing contains many strange concepts.
·í§Ú̧â [ Solve for? ] ©ñ¦b [ n ] (Sample size)
¦Ó§â Power (1-£] ) , Significance level ( £\ = 0.05 ) , Effect size ( Cohen¡¦s d ) °µ¨Ç½Õ¾ãÅܤÆ
§ÚÌ´N¥i¥H±q¹Ï«¬ªºÅÜ¤Æ ÁÙ¦³¼Ë¥»¼Æ¤j¤pªº¼W´î
±q¦Ó¤F¸Ñ SND-13 ªºÁ{§É²Îp³]©w
[[
• Phase II/III registrational trial is designed to detect an ES >= 0.5 with 85% power
• A sample size reassessment and adjustment will be performed prior to
enrolling the remaining patients to be able to detect an ES >= 0.2* with 80% power on the entire trial
( * ES=0.2 is the minimally clinical meaningful treatment effect. )
]]
¬O§_«O¦u¤F?
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
1¡þ3ªA¥Î³B¤èÃÄ¥Á²³ ¬ã¨s¡G®£P¼~Æ{©Î¦Û±þ
2018¦~06¤ë14¤é ¤¤®É¹q¤l³ø ³¯µÎ¯³
www.chinatimes.com/realtimenews/20180614001009-260408
¬ü°ê³Ì·sÂå¾Ç¬ã¨s«ü¥X¡A¹O¤T¤À¤§¤@¬ü°ê¦¨¦~¤H©ÒªA¥Îªº³B¤èÃÄ«~¡A°Æ§@¥Î¥]¬A¥i¯à¾ÉP¼~Æ{¯g¡A©Î¼W¥[¦Û±þ¶É¦V¡C
¡u¬ü°êÂå¾Ç·|´Á¥Z¡v¡]Journal of the American Medical Association¡^12¤é¥Zµn³Ì·sÂå¾Ç¬ã¨s¡A°w¹ï2005¦~¦Ü2014¦~¶¡¡A¥þ¬ü¦U¦a2¸U6000¦W¦¨¦~¤HªºÃĪ«¨Ï¥Î¶i¦æ¤ÀªR¡Aµ²ªGµo²{¬Y¨Ç¶W¹L200ºØ¬ü°ê¥Á²³³Ì±`ªA¥Îªº200ºØ³B¤èÃĪ«¡A¼ç¦b°Æ§@¥Î¥]¬A¾ÉP¼~Æ{¯g©Î¦Û±þ¡C
²Îpµo²{¡A®£¾ÉP¼~Æ{¯g¡B¦Û±þ·ÀIªº³B¤èÃĪ«·í¤¤¡A¥]¬A¤F²üº¸»XÁ×¥¥ÃÄ¡B¤ßŦÃÄ¡B¦åÀ£±±¨îÃÄ¡B²BÂ÷¤lÀ°®ú§í¨î¾¯¡]proton-pump inhibitors¡A²ºÙPPIs¡^¡B¨î»Ä¾¯¡]antacids¡^¡B¤îµh¾¯µ¥¡C¦pªG¦¨¦~¤H¦P®ÉªA¥Î¤TºØ¥H¤W¡A¬ù¦³15%±Nµo²{¦Û¤vªAÃÄ´Á¶¡¥X²{¼~Æ{¯g¡F¥u¦³ªA¥Î¤@ºØ¥H¤WÃĪ«ªº¦¨¦~¤H¸Ì¡A¥u¦³7%ªí¥ÜªAÃÄ´Á¶¡¥X²{¼~Æ{¯g¡AªA¥Î¨âºØ¥H¤WÃĪ«ªÌ«h¦³9%»¡²£¥Í¼~Æ{¯g¡C
(¤¤®É¹q¤l³ø)
¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-06-12
med.sina.com/article_detail_103_2_47343.html
6¤ë12¤é¡A§¨Ó¤½¥q«Å¥¬¡A¨ä©Mªü´µ§Q±d¤½¥q¥¿¦b°±¤î¤fªA£]¤Àªc酶µõ¸Ñ酶¡]BACE¡^§í»s¾¯LanabecestatªvÀøªüº¸¯ý®üÀq¯fªº¥þ²y3´ÁÁ{§É¸ÕÅç¡C¸Ó¨M©w°ò©ó¿W¥ß¼Æ¾ÚºÊ´ú©eû·|¡]IDMC¡^ªº«Øij¡A¸Ó©eû·|±o¥Xªºµ²½×¡G¦´Áªüº¸¯ý®üÀq¯f¸ÕÅçAMARANTH©M°w¹ï»´«×ªüº¸¯ý®üÀq¯fè§bªº¸ÕÅçDAYBREAK-ALZ³£¤£¥i¯à¹F¨ì¨ä¥Dn²×ÂI¡A¦]¦¹À³¸Ó°±¤î¡C§@¬°³o¤@¨M©wªºµ²ªG¡AAMARANTHÂX®i¸ÕÅç¤]±N°±¤î¡C
§Ñ¤F¶K¤W³sµ²
med.sina.com/article_detail_103_2_47229.html